beta
/First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity
Abstract

Abstract N/A

RelatedView All
CitationsView All
Citing25
Cited By-